MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s completed clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has been accepted for oral presentation at the 29th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held December 7 - 9, 2018 in Glasgow, Scotland, UK. The oral presentation entitled "Novel Composite Endpoint Extended Analysis during Extension of Ibudilast Phase 1b/2a Clinical Trial Better Predicts Post-Wash-Out Survival” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute. Presentation details are as follows: Session Date and Time: Friday December 7, 2018, 4:50 –
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)GlobeNewswire
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago [Yahoo! Finance]Yahoo! Finance
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
MNOV
Earnings
- 5/9/24 - Miss
MNOV
Sec Filings
- 5/9/24 - Form 10-Q
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- MNOV's page on the SEC website